S
Sarah E. Gelfand
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 6
Citations - 1360
Sarah E. Gelfand is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Randomized controlled trial & Epidemiology. The author has an hindex of 5, co-authored 6 publications receiving 1311 citations.
Papers
More filters
Journal ArticleDOI
The Influence of Hospital Volume on Survival after Resection for Lung Cancer
Peter B. Bach,Laura D. Cramer,Deborah Schrag,Robert J. Downey,Sarah E. Gelfand,Colin B. Begg +5 more
TL;DR: Patients who undergo resection for lung cancer at hospitals that perform large numbers of such procedures are likely to survive longer than patients who have such surgery at hospitals with a low volume of lung-resection procedures.
Journal ArticleDOI
Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence.
TL;DR: The primary aims of this paper are to summarize and evaluate published data that address care of patients with acute exacerbations of chronic obstructive pulmonary disease and to improve the care that these patients receive by identifying efficacious and inefficacious treatment strategies.
Journal ArticleDOI
Management of acute exacerbations of COPD: a summary and appraisal of published evidence.
TL;DR: Although suggestions for appropriate management can be made based on available evidence, the supporting literature is spotty and will require an improved, generally acceptable, and transportable definition of the syndrome "acute exacerbation of COPD" and improved methods for observing and measuring outcomes.
Journal ArticleDOI
Who Gets Adjuvant Treatment for Stage II and III Rectal Cancer? Insight From Surveillance, Epidemiology, and End Results–Medicare
TL;DR: Patients were more likely to receive radiation treatment if they had an abdominal perineal resection, stage III disease, or a T4 tumor, and further efforts are needed to ensure that elderly patients have the opportunity to make informed decisions regarding adjuvant treatment.
Journal ArticleDOI
Impact of infection by vancomycin-resistant Enterococcus on survival and resource utilization for patients with leukemia.
Peter B. Bach,Sharp F. Malak,Joseph Jurcic,Sarah E. Gelfand,Janet Eagan,Claudia Little,Kent A. Sepkowitz +6 more
TL;DR: Findings substantiate the need for aggressive interventions to prevent VRE transmission and confirm the importance of vaccination against vancomycin-resistant Enterococcus.